The latest news updates from the 2024 Symposium
Six concurrent poster spotlight sessions throughout this year’s Symposium will showcase top-rated abstracts that have the potential to shape future clinical practice. Andrea V. Barrio, MD, FACS, offers insight into topics that will be presented Tuesday evening.
Kerry S. Courneya, PhD, discusses a Tuesday afternoon presentation on the impact of exercise on breast cancer outcomes.
Christine Desmedt, PhD, discusses a Tuesday afternoon presentation on the biological peculiarities of invasive lobular breast cancer.
Carlos H. Barrios, MD, discusses a Tuesday afternoon presentation on single agent endocrine therapy post-CDK 4/6 inhibitors in metastatic HR+ breast cancer.
Jai Min Ryu, MD, PhD, discusses a Tuesday evening poster presentation on the clinicopathologic characteristics and axillary lymph node status of patients enrolled in the NAUTILUS trial.
Bruce Mann, MBBS, PhD, FRACS, discusses a Tuesday evening poster presentation on the impact of treatment de-escalation on fear of cancer recurrence and health-related quality of life.
Fabiana Napolitano, MD; Carmen van Dooijeweert, MD, PhD; and Marcelo Sobral-Leite, PharmD, PhD, discuss their Tuesday evening poster presentations.
Three concurrent Special Sessions on Tuesday will cover topics including new drug approvals for metastatic breast cancer and the prevention, early detection, and interception of breast cancer. Amelie G. Ramirez, DrPH, MPH, will moderate a session and panel discussion on social determinants of health in cancer care.
Sessions throughout the Symposium will explore clinical cases from the perspective of experts including Martine J. Piccart, MD, PhD, and Virginia F. Borges, MD.
Kornelia Polyak, MD, PhD, FAACR, left, and Alana L. Welm, PhD, right, will be honored with awards from the American Association for Cancer Research (AACR) for significant contributions to breast cancer research.